The partnership will provide integration of technologies and processes, giving biopharmaceutical companies near real-time, consistent and reliable medical imaging information to expedite their drug development programs.
The integration of services between PPD and VirtualScopics will establish a more efficient, tailored approach across several key areas of the clinical trial process, including study startup, screening and enrollment, accurate determination of endpoints for radiographic response and progression, management of imaging data and proactive risk management.
The alliance with VirtualScopics will enhance PPD’s ability to provide clients with the full service, integrated solutions needed to progress drug development from early phase to regulatory approval through a patented algorithm-based approach to image processing and biomarker measurement.
PPD CEO David Grange said that the partnership expands their ability to deliver the development services in oncology, and are pleased to partner with VirtualScopics.
VirtualScopics president and chief executive officer Jeff Markin said that through the close relationship with PPD, they will be able to reach an expanded set of customers with an integrated approach to managing each of these areas.